1. Home
  2. MLCO vs ANIP Comparison

MLCO vs ANIP Comparison

Compare MLCO & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Melco Resorts & Entertainment Limited

MLCO

Melco Resorts & Entertainment Limited

N/A

Current Price

$4.24

Market Cap

1.6B

ML Signal

N/A

Logo ANI Pharmaceuticals Inc.

ANIP

ANI Pharmaceuticals Inc.

N/A

Current Price

$73.61

Market Cap

1.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MLCO
ANIP
Founded
2003
2001
Country
Hong Kong
United States
Employees
22961
N/A
Industry
Hotels/Resorts
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.9B
IPO Year
2006
1999

Fundamental Metrics

Financial Performance
Metric
MLCO
ANIP
Price
$4.24
$73.61
Analyst Decision
Buy
Buy
Analyst Count
13
9
Target Price
$7.06
★ $105.78
AVG Volume (30 Days)
★ 1.8M
345.1K
Earning Date
11-05-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 419.23
EPS
N/A
★ 2.32
Revenue
N/A
★ $206,547,000.00
Revenue This Year
$1.93
$24.85
Revenue Next Year
$4.38
$10.76
P/E Ratio
★ $12.16
$31.03
Revenue Growth
N/A
★ 2.47
52 Week Low
$4.07
$69.58
52 Week High
$9.53
$96.99

Technical Indicators

Market Signals
Indicator
MLCO
ANIP
Relative Strength Index (RSI) 32.92 50.75
Support Level $4.07 $73.71
Resistance Level $5.73 $83.03
Average True Range (ATR) 0.15 2.16
MACD -0.01 -0.03
Stochastic Oscillator 24.24 34.59

Price Performance

Historical Comparison
MLCO
ANIP

About MLCO Melco Resorts & Entertainment Limited

Melco Resorts & Entertainment is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs' electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 84% from Macao, with the rest from overseas as of 2025.

About ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.

Share on Social Networks: